IP Library › Granted Patent US 12,220,558
Granted Patent B2
US 12,220,558 · App. 17/567,684 · Granted Feb 11, 2025

Continuous glucose monitoring system

Inventors: Mark Sloan (Redwood City, CA); Marc B. Taub (Mountainview, CA); Charles Wei (Fremont, CA)
Assignee: ABBOTT DIABETES CARE INC.
A61M5/1723A61B5/14532A61B5/4839A61B5/746A61M5/142G08B21/0453G08B21/182G16H20/17G16H50/50A61M2005/14296A61M2205/18A61M2205/3569A61M2205/52A61M2230/201G16H40/67
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,558
App. No.
17/567,684
Granted
Feb 11, 2025
Kind
B2
Abstract

Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.

Claims (38)

1. A method for providing notifications related to a predicted glucose level for a user, comprising:

detecting a glucose level of the user using an analyte sensor;

determining a predicted glucose level for a future time period during which the user is unable to take corrective action;

generating, by a user interface, one or more notifications related to the predicted glucose level for the future time period, wherein the one or more notifications comprises a corrective action to adjust the glucose level of the user; and

receiving a selection by the user to implement the corrective action.

2. The method of claim 1 , wherein the one or more notifications are generated based upon the predicted glucose level crossing one or more predetermined analyte thresholds.

3. The method of claim 2 , wherein the predetermined glucose threshold comprises a low glucose level.

4. The method of claim 2 , wherein the one or more predetermined analyte thresholds are received prophylactically in preparation of the period during which the user is unable to take corrective action.

5. The method of claim 1 , wherein the one or more notifications comprise a recommendation to ingest an amount of carbohydrates.

6. The method of claim 5 , wherein the amount of carbohydrates is calculated based on the detected glucose level.

7. The method of claim 1 , wherein the one or more notifications comprise a recommendation to reduce a basal rate of a medication delivery device of the user.

8. The method of claim 1 , wherein the one or more notifications comprise a recommendation to increase a time horizon of a medication delivery device of the user.

9. The method of claim 1 , further comprising implementing the corrective action to prevent the user's glucose level from crossing one or more predetermined analyte thresholds during the future period.

10. The method of claim 1 , further comprising calculating a glucose level profile of the user based on the detected glucose level of the user and one or more parameters, wherein the predicted glucose level is determined based upon the calculated glucose profile.

11. The method of claim 1 , wherein the one or more notifications is displayed on the user interface.

12. The method of claim 1 , further comprising, receiving the future time period during which the user is unable to take corrective action and wherein the generated one or more notifications are provided before a beginning of the future time period during which the user is unable to take corrective action.

13. The method of claim 12 , wherein the received futured time period during which the user is unable to take corrective action is input into the user interface.

14. An analyte monitoring system for providing notifications related to a predicted glucose level for a user, comprising:

an analyte sensor when at least partially inserted into interstitial fluid of the user is configured to detect a glucose level of the user;

a user interface;

a processor operably coupled to the analyte sensor; and

a memory operably coupled to the processor, wherein the memory includes instructions stored therein that, when executed by the processor, cause the processor to:

detect the glucose level using the analyte sensor;

determine the predicted glucose level for a future time period during which the user is unable to take corrective action;

generate, by the user interface, one or more notifications related to the predicted glucose level for the future time period, wherein the one or more notifications comprises a corrective action to adjust the glucose level of the user; and

receive a selection by the user to implement the corrective action.

15. The system of claim 14 , wherein the analyte sensor is a glucose sensor.

16. The system of claim 14 , wherein the one or more notifications are generated based upon the predicted glucose level crossing one or more predetermined glucose thresholds.

17. The system of claim 16 , wherein the predetermined glucose threshold comprises a low glucose level.

18. The system of claim 14 , wherein the one or more notifications comprise a recommendation to ingest an amount of carbohydrates.

19. The system of claim 18 , wherein the amount of carbohydrates is calculated based on the detected glucose level.

20. The system of claim 14 , wherein the one or more notifications comprise a recommendation to reduce a basal rate of a medication delivery device of the user.

21. The system of claim 14 , wherein the one or more notifications comprise a recommendation to increase a time horizon of a medication delivery device of the user.

22. The system of claim 14 , wherein the system is further in communication with a medication delivery device.

23. The system of claim 14 , the memory further comprises instructions to calculate a glucose level profile of the user based on the detected glucose level of the user and one or more parameters, wherein the predicted glucose level is determined based upon the calculated glucose profile.

24. The system of claim 14 , wherein the one or more notifications is displayed on the user interface.

25. The system of claim 14 , the instructions further comprising, receive the future time period during which the user is unable to take corrective action and wherein the generated one or more notifications are provided before a beginning of the future time period during which the user is unable to take corrective action.

26. The system of claim 25 , wherein the received futured time period during which the user is unable to take corrective action is input into the user interface.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2022
From: SLOAN, MARK; TAUB, MARC B.; HAYTER, GARY A.; HARPER, WESLEY SCOTT; BUDIMAN, ERWIN S.; WEI, CHARLES
To: ABBOTT DIABETES CARE INC.
Reel/Frame 058867/0342 →
Continuity (6)
Continuation 16560497 · Sep 4, 2019
Continuation 15282688 · Sep 30, 2016
Division 14076109 · Nov 8, 2013
Continuation 12785144 · May 21, 2010
Provisional Application 61180649 · May 22, 2009
Related Publication 20220118180A1 · Apr 21, 2022
References Cited (179)
US 5569186A · Lord et al. · 1996 [cited by applicant]
US 5665065A · Colman et al. · 1997 [cited by applicant]
US 5822715A · Worthington et al. · 1998 [cited by applicant]
US 6175752B1 · Say et al. · 2001 [cited by applicant]
US 6544212B2 · Galley et al. · 2003 [cited by applicant]
US 6923763B1 · Kovatchev et al. · 2005 [cited by applicant]
US 7278983B2 · Ireland et al. · 2007 [cited by applicant]
US 7976492B2 · Brauker · 2011 [cited by examiner]
US 8073008B2 · Mehta et al. · 2011 [cited by applicant]
US 8282549B2 · Brauker et al. · 2012 [cited by applicant]
US 8417312B2 · Kamath · 2013 [cited by examiner]
US 8597274B2 · Sloan · 2013 [cited by examiner]
US 10980461B2 · Simpson et al. · 2021 [cited by applicant]
US 11213622B2 · Sloan · 2022 [cited by examiner]
US 20020045808A1 · Ford et al. · 2002 [cited by applicant]
US 20030114836A1 · Estes et al. · 2003 [cited by applicant]
US 20030163789A1 · Blomquist · 2003 [cited by applicant]
US 20050038332A1 · Saidara et al. · 2005 [cited by applicant]
US 20050171513A1 · Mann et al. · 2005 [cited by applicant]
US 20050195930A1 · Spital et al. · 2005 [cited by applicant]
US 20060087655A1 · Augustine et al. · 2006 [cited by applicant]
US 20060173406A1 · Hayes et al. · 2006 [cited by applicant]
US 20060276771A1 · Galley et al. · 2006 [cited by applicant]
US 20070052965A1 · Pesach et al. · 2007 [cited by applicant]
US 20070078314A1 · Grounsell et al. · 2007 [cited by applicant]
US 20070106135A1 · Sloan et al. · 2007 [cited by applicant]
US 20070118030A1 · Bruce et al. · 2007 [cited by applicant]
US 20070149874A1 · Say et al. · 2007 [cited by applicant]
US 20070170054A2 · Wilsey · 2007 [cited by applicant]
US 20070173761A1 · Kanderian, Jr. et al. · 2007 [cited by applicant]
US 20070179370A1 · Say et al. · 2007 [cited by applicant]
US 20070208244A1 · Brauker et al. · 2007 [cited by applicant]
US 20070213657A1 · Jennewine · 2007 [cited by examiner]
US 20070235331A1 · Simpson et al. · 2007 [cited by applicant]
US 20080119710A1 · Reggiardo et al. · 2008 [cited by applicant]
US 20080149821A1 · Senko · 2008 [cited by applicant]
US 20080172026A1 · Blomquist · 2008 [cited by applicant]
US 20080172030A1 · Blomquist · 2008 [cited by applicant]
US 20080172031A1 · Blomquist · 2008 [cited by applicant]
US 20080235053A1 · Ray et al. · 2008 [cited by applicant]
US 20080262469A1 · Brister et al. · 2008 [cited by applicant]
US 20080300572A1 · Rankers et al. · 2008 [cited by applicant]
US 20080306444A1 · Brister · 2008 [cited by examiner]
US 20090006129A1 · Thukral et al. · 2009 [cited by applicant]
US 20090055149A1 · Hayter et al. · 2009 [cited by applicant]
US 20090114811A1 · Landgraf · 2009 [cited by applicant]
US 20090192366A1 · Mensinger et al. · 2009 [cited by applicant]
US 20090192380A1 · Shariati et al. · 2009 [cited by applicant]
US 20090216102A1 · Say et al. · 2009 [cited by applicant]
US 20090221890A1 · Saffer et al. · 2009 [cited by applicant]
US 20090254037A1 · Bryant et al. · 2009 [cited by applicant]
US 20090275887A1 · Estes · 2009 [cited by applicant]
US 20100017141A1 · Campbell et al. · 2010 [cited by applicant]
US 20100049164A1 · Estes · 2010 [cited by applicant]
US 20100161236A1 · Cohen et al. · 2010 [cited by applicant]
US 20100191472A1 · Doniger et al. · 2010 [cited by applicant]
US 20100198314A1 · Wei · 2010 [cited by applicant]
US 20100280441A1 · Wilinska et al. · 2010 [cited by applicant]
US 20110077494A1 · Doniger et al. · 2011 [cited by applicant]
US 20110124996A1 · Reinke et al. · 2011 [cited by applicant]
US 20140039383A1 · Dobbles et al. · 2014 [cited by applicant]
US 20140052095A1 · Dobbles · 2014 [cited by examiner]
US 20140350371A1 · Blomquist et al. · 2014 [cited by applicant]
US 20150094914A1 · Abreu · 2015 [cited by applicant]
WO WO9956613 · 1999 [cited by applicant]
WO WO2004009161 · 2004 [cited by applicant]
WO WO2006079867 · 2006 [cited by applicant]
WO WO2008030347 · 2008 [cited by applicant]
WO WO2008151452 · 2008 [cited by applicant]
WO WO2009049252 · 2009 [cited by applicant]
WO WO2009146119 · 2009 [cited by applicant]
WO WO2011041007 · 2011 [cited by applicant]
WO WO2011060923 · 2011 [cited by applicant]
Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: In Vivo Glucose Sensing, Chemical Analysis, A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley (2010). [cited by applicant]
Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval (2011). [cited by applicant]
Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Bailey, et al., Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study, Diabetes Te… [cited by applicant]
Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor, Diabetes Care, vol. 29, No. 1, pp. 4… [cited by applicant]
Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Relationship of Fasting and Hourly Blood Glucose Levels to HbAlc Values, Diabetes Care, vol. 29, No. 12, pp. 2644-2649 (2006). [cited by applicant]
Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Welcome to Your FreeStyle Libre System, In-Service Guide, Abbott (2017). [cited by applicant]
Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Standards of Medical Care in Diabetes-2009, American Diabetes Association, Diabetes Care, vol. 32, Supplement 1, pp. S13-S61 (2009). [cited by applicant]
Exhibit No. 23, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® System Gold™ Continuous Glucose Monitoring Overview, Medtronic MiniMed (2004). [cited by applicant]
Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, J Diabetes Sci Technol vol. 1, Issue 5, pp. 669-675 (2007). [cited by applicant]
Exhibit No. 19, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Glucose Concentrations of Less Than 3.9 mmol/L (54 mg/dL) Should be Reported in Clinical Trials: A Joint Position Statement of the America Di… [cited by applicant]
Exhibit No. 18, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Aleppo, et al., REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in A… [cited by applicant]
Exhibit No. 17, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Diabetes (type 1), NIHR (2011). [cited by applicant]
Exhibit No. 16, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Pickup, et al., Glycaemic control in type 1 diabetes during real time continous glucose monitoring compared with self minotoring of blood glu… [cited by applicant]
Exhibit No. 15, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011). [cited by applicant]
Exhibit No. 14, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, Clinical Guideline 15, NHS, National Insti… [cited by applicant]
Exhibit No. 13, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Training in flexible, intensive, insulin mangement to enable dietrary freedom in people with type 1 diabetes: dose adjustment for normal eati… [cited by applicant]
Exhibit No. 12, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Modern Standards and Service Models, Diabetes, National Service Framework for Diabetes: Standards, Department of Health (2000). [cited by applicant]
Exhibit No. 11, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mel… [cited by applicant]
Exhibit No. 10, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 Diabetes Research Roadmap, Identifying the strengths and weaknesses, gaps and opportunities of UK type 1 diabetes research; clearing a… [cited by applicant]
Exhibit No. 9, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, European Medicines Agency, Scie… [cited by applicant]
Exhibit No. 8, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011). [cited by applicant]
Exhibit No. 7, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Cryer, Preventing hypoglycaemia: what is the appropriate glucose alert value?, Diabetologia, vol. 52, pp. 35-37 (2009). [cited by applicant]
Exhibit No. 6, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Frier, Defining hypoglycaemia: what level has clinical relevance?, Diabetologia, vol. 52, pp. 31-34 (2009). [cited by applicant]
Exhibit No. 5, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Swinnen, et al., Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, Di… [cited by applicant]
Exhibit No. 4, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Amiel, et al., Review Article, Hypoglycaemia in Type 2 diabetes, Diabetic Medicine, vol. 25, pp. 245-254 (2008). [cited by applicant]
Exhibit No. 3, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Defining and Reporting Hypoglycemia in Diabetes, Diabetes Care, vol. 28, No. 5, pp. 1245-1249 (2005). [cited by applicant]
Exhibit No. 2, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Dia… [cited by applicant]
Exhibit No. 28, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator II, Continuous Glucose Monitoring System, User's Manual, Abbott (2011-2013). [cited by applicant]
Exhibit No. 27, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott (2008, 2010). [cited by applicant]
Exhibit No. 26, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® iPro™ Continuous Glucose Recorder, User Guide, Medtronic MiniMed (2007). [cited by applicant]
Exhibit No. 25, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed (2006). [cited by applicant]
Exhibit No. 24, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: GlucoWatch G2, Automatic Glucose Biographer and Auto Sensors (2002). [cited by applicant]
Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, Journal of Diabetes Science and Technology, vol. 1, Issue 5, pp. 66… [cited by applicant]
Exhibit No. 29, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Dexcom G4, Continuous Glucose Monitoring System, User's Guide (2013). [cited by applicant]
Exhibit No. 31, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for EP625. [cited by applicant]
Exhibit No. 32, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Puhr, et al., Real-World Hypoglycemia Avoidance with a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views, Journal of Diab… [cited by applicant]
Exhibit No. 33, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Rilstone, et al., The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for peoper with type… [cited by applicant]
Exhibit No. 34, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2019-2021). [cited by applicant]
Exhibit No. 35, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2022). [cited by applicant]
Exhibit No. 30, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for US 2007/208244A1. [cited by applicant]
Exhibit No. 22, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Innovation Milestones, et al. [cited by applicant]
Exhibit No. 21, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: DeVries, Glucose Sensing Issues for the Artificial Pancreas, Journal of Diabetes Science and Technology, vol. 2, Issue 4, pp. 732-734 (2008). [cited by applicant]
Exhibit No. 37, to the Second Expert Report of Professor Nick Oliver, Oct. 21, 2022: Oliver, et al., Review Article, Glucose sensors, a review of current and emerging technology, Diabetic Medicine, vol. 26, pp. 197-210 … [cited by applicant]
U.S. Appl. No. 16/560,497 (U.S. Pat. No. 11,213,622) filed Sep. 4, 2019 (Jan. 4, 2022). [cited by applicant]
U.S. Appl. No. 15/282,688 (US 2017-0035969 A1) filed Sep. 30, 2016 (Feb. 9, 2017). [cited by applicant]
U.S. Appl. No. 14/076,109 (US 2014-0066890 A1) filed Nov. 8, 2013 (Mar. 6, 2014). [cited by applicant]
U.S. Appl. No. 12/785,144 (U.S. Pat. No. 8,597,274) filed May 21, 2010 (Dec. 3, 2013). [cited by applicant]
U.S. Appl. No. 16/560,497, filed Nov. 23, 2021 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 16/560,497, filed Aug. 25, 2021 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 16/560,497, filed Aug. 10, 2021 Response to Final Office Action and Request for Continued Examination (RCE). [cited by applicant]
U.S. Appl. No. 16/560,497, filed May 10, 2021 Final Office Action. [cited by applicant]
U.S. Appl. No. 16/560,497, filed Mar. 17, 2021 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 16/560,497, filed Nov. 23, 2020 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/282,688, filed Oct. 10, 2019 Abandonment. [cited by applicant]
U.S. Appl. No. 15/282,688, filed Apr. 4, 2019 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Dec. 15, 2016 Abandonment. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Jun. 2, 2016 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Apr. 22, 2016 Response to Final Office Action and Request for Continued Examination (RCE). [cited by applicant]
U.S. Appl. No. 14/076,109, filed Jan. 22, 2016 Final Office Action. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Nov. 9, 2015 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Jun. 11, 2015 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 14/076,109, filed May 26, 2015 Response to Restriction Requirement. [cited by applicant]
U.S. Appl. No. 14/076,109, filed Mar. 24, 2015 Restriction Requirement. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Oct. 29, 2013 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Sep. 3, 2013 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Jun. 26, 2013 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Mar. 27, 2013 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Mar. 18, 2013 Response to Restriction Requirement. [cited by applicant]
U.S. Appl. No. 12/785,144, filed Jan. 18, 2013 Restriction Requirement. [cited by applicant]
“convolution,” Wikipedia, retrieved on May 28, 2016, retrieved from: https://en.wikipedia.org/wiki/Convolution, pp. 1-14. [cited by applicant]
U.S. Appl. No. 61/246,630, filed Sep. 29, 2009. [cited by applicant]
“Getting Started with Carelink™ Personal Software For Continuous Glucose Monitoring”, User Guide, Medtronic Diabetes, 28 pages (2009). [cited by applicant]
“In Vivo Glucose Sensing”, Chemical Analysis, A Series of Monographs on Analytical Chemistry and its Applications, vol. 174, 466 pages (2010). [cited by applicant]
“PMA Approvals” retrieved from “https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/pma-approvals#monthly” on Sep. 14, 2022, 3 pages. [cited by applicant]
“Premarket Approval (PMA)” retrieved from “https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P050020” on Sep. 14, 2022, 6 pages. [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, User Guide, Abbott Diabetes Care Inc., 195 pages (2008). [cited by applicant]
Sandham, et al., “Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network”, 9th European Signal Processing Conference (EUSIPCO 1998), 4 pages (1998). [cited by applicant]
Sparacino, et al., “Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series”, IEEE Transactions on Biomedical Engineering, 54(5):931-937 (2007). [cited by applicant]
U.S. Appl. No. 17/941,586, filed Feb. 28, 2023 Notice of Allowance. [cited by applicant]
“DexCom's 7-Day STS Continuous Glucose Monitoring System”, Jun. 1, 2007 https://newatlas.com/dexcoms-7-day-sts-continuous-glucose-monitoring-system/7376/ 1 page. [cited by applicant]
About Dexcom—Continuous Glucose Monitoring Company, 12 pages (2021). [cited by applicant]
Alva, S., et al., Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes, Journal of Diabetes Science and Technology, vol. 16… [cited by applicant]
Campbell, F. M., et al., Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study, Pediatric Diabetes, pp. 1294-1301 (2018). [cited by applicant]
Deshmukh, H., et al., Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Aud… [cited by applicant]
General report of the German Diabetes Society on the state of diabetic patients and treatment methods for the year 2021, 15 pages (with English summary). [cited by applicant]
Haak, T., et al., Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes, Diabetes Ther, 14 pages (2017). [cited by applicant]
Letter from Department of Health & Human Services, Food and Drug Administration, to Andy Balo, DexCom, Inc. re. P050012/S001, STS-7 Continuous Glucose Monitoring System dated May 31, 2007, 95 pages. [cited by applicant]
Roussel, R., et al., Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The Relief Study, 5 pages, American Diabetes A… [cited by applicant]
STS®—Seven Continuous Glucose Monitoring System User's Guide, 74 pages (2007). [cited by applicant]
Summary of Safety and Effectiveness Data, STS®—7 Continuous Glucose Monitoring System, DexCom, Inc., Date of Approval: May 31, 2007, 14 pages. [cited by applicant]
Approval letter from Department of Health and Human Services re. P050012/S001, STS-7 Continuous Glucose Monitoring System, dated May 31, 2007, 7 pages. [cited by applicant]
Declaration of Thomas Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A3TR (“Taylor Wessing”), signed on Jan. 30, 2024 (160 pages). [cited by applicant]
PMA Final Decisions Rendered for May 2007, The Wayback Machine, U.S. Food and Drug Administration, 21 pages. [cited by applicant]
Premarket Approval (PMA) on Seven Plus Continuous Glucose Monitoring System, Notice date: Jun. 28, 2007, 3 pages. [cited by applicant]
STS-7 Continuous Glucose Monitoring System—P050012/S001, Approved May 31, 2007, The Wayback Machine, U.S. Food and Drug Administration, 1 page. [cited by applicant]
Choudhary, et al., Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia, Reduction in nocturnal hypoglycemia in those at greatest risk, Diabetes Care, vol. 34, pp. 2023-2025 (2011). [cited by applicant]
Congress.gov, About the Congressional Record, Feb. 22, 2022, 3 pages. [cited by applicant]
Declaration of Thomas Edward Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A 3TR (“Taylor Wessing”), signed on Jan. 30, 2024, 160 pages. [cited by applicant]
FDA Premarket Approval (PMA) for Seven Plus Continuous Glucose Monitoring System, Notice Date: Jun. 28, 2007, 3 pages. [cited by applicant]
Federal Register, vol. 76, No. 120, Jun. 22, 2011, pp. 36542-36543. [cited by applicant]
Hon, Urging FDA to Act Promptly to Approve Artificial Pancreas Technologies, Congressional Record (Bound Edition), vol. 157 (2011), Part 13, 3 pages. [cited by applicant]
Kowalski, Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes, Diabetes Technology & Therapeutics, vol. 11, pp. S-113-S-119 (2009). [cited by applicant]
Letter from Department of Health & Human Services to Mr. Andy Balo, Dexcom, Inc. re. P050012/S001, STS-7 Continuous Glucose Monitoring System, dated May 31, 2007, 7 pages. [cited by applicant]
Pickup, et al., Semi-Closed-Loop Insulin Delivery Systems: Early Experience with Low-Glucose Insulin Suspend Pumps, Diabetes Technology & Therapeutics, vol. 13, No. 7, pp. 695-698 (2011). [cited by applicant]
PMA Final Decisions Rendered for May 2007, FDA U.S. Food and Drug Administration, 21 pages. [cited by applicant]
STS-7 Continuous Glucose Monitoring System—P050012/S001, Approved May 31, 2007, FDA U.S. Food and Drug Administration, 1 page. [cited by applicant]